44. Kshirsagar AV, Freburger JK, Ellis AR et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. Results. Vitamin K antagonist use as compared with no vitamin K antagonist use was associated with a 1.2-fold [95% confidence interval (95% CI) 1.0-1.5] increased all-cause mortality risk, a 1.5-fold (95% CI 0.6-4.0) increased stroke mortality risk, a 1.3-fold (95% CI 0.4-4.2) increased bleeding mortality risk, a 1.2-fold (95% CI 0.9-1.8) increased cardiovascular mortality risk and a 1.2-fold (95% CI 0.8-1.6) increased other mortality risk after adjustment. Within patients with a CHA 2 DS 2 -VASc score 1, vitamin K antagonist use was associated with a 2.8-fold (95% CI 1.0-7.8) increased all-cause mortality risk as compared with no vitamin K antagonist use, while vitamin K antagonist use within patients with a CHA 2 DS 2 -VASc score !2 was not associated with an increased mortality risk after adjustment. Conclusion. Vitamin K antagonist use was not associated with a protective effect on mortality in the different CHA 2 DS 2 -VASc scores in dialysis patients. The lack of knowledge on the indication for vitamin K antagonist use could lead to confounding by indication.
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I N T R O D U C T I O N
Vitamin K antagonists are used to prevent stroke in patients with an increased risk of stroke due to atrial fibrillation [1, 2] . Current American College of Cardiology/American Heart Association atrial fibrillation guidelines and European Society of Cardiology guidelines for the management of atrial fibrillation suggest the consideration of vitamin K antagonist prescription for those with high stroke risks based on increased CHA 2 DS 2 -VASc scores (score !2) [1, 2] . These guidelines are based on several clinical trials in the general population, in which benefits of vitamin K antagonists outweigh the risks of bleeding for patients with an increased stroke risk [3, 4] .
The risk-benefit ratio of vitamin K antagonists in patients with end-stage renal disease treated with dialysis and atrial fibrillation is unknown. This is underlined by the 2016 European Society of Cardiology guideline stating the need for research in this patient group [2] . Previous studies that investigated the effect of vitamin K antagonists in dialysis patients showed conflicting results [5] [6] [7] [8] [9] [10] [11] [12] [13] . Only two of these studies showed a decreased risk of stroke [5] or a survival benefit [6] for vitamin K antagonist use as compared with no vitamin K antagonist use in dialysis patients, while all other studies did not show a protective effect of vitamin K antagonists on stroke risk or all-cause mortality [9] [10] [11] [12] [13] [14] . The studies showing a decreased risk had several limitations, including limited adjustment for confounders. Furthermore, these studies also included transplantation patients. A meta-analysis performed in over 9800 dialysis patients with atrial fibrillation showed that vitamin K antagonist treatment was associated with a 1.2-fold [95% confidence interval (95% CI) 0.8-1.9] increased stroke risk [7] . Several studies showed an increased bleeding risk for vitamin K antagonists [13, 15] . It is plausible that pre-existing platelet dysfunction, routine heparin use during haemodialysis treatment and a suboptimal time in therapeutic range leads to increased risks of bleeding complications in dialysis patients [16, 17] . Because of the higher bleeding risk in dialysis patients compared with the general population, it could be that vitamin K antagonists are only beneficial in higher CHA 2 DS 2 -VASc scores (i.e. higher stroke risks) than the cut-off score 2 used in the general population. However, studies investigating the association between vitamin K antagonist use and mortality for different CHA 2 DS 2 -VASc scores in dialysis patients are lacking.
Therefore, the aim of this study was to investigate the association between vitamin K antagonist use and mortality for different CHA 2 DS 2 -VASc scores in a cohort of end-stage renal disease patients with and without atrial fibrillation receiving dialysis treatment.
M A T E R I A L S A N D M E T H O D S

Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a prospective multicentre cohort study in which incident adult end-stage renal disease patients in the Netherlands were included. Eligibility included age >18 years, and no previous renal replacement therapy. All patients gave informed consent and the study was approved by all local medical ethics committees. We followed patients until death or censoring, i.e. transfer to a non-participating dialysis centre, withdrawal from the study, transplantation or end of the follow-up period (February 2015).
Demographic and clinical data
Data on age, sex, primary kidney disease, dialysis modality and gastro-intestinal problems including bleeding, malignancy and cardiovascular disease (angina pectoris, myocardial infarction, heart failure, ischaemic stroke or claudication) were collected at the start of dialysis treatment. Primary kidney disease was classified according to the codes of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) [18] . We grouped patients into four classes of primary kidney disease: glomerulonephritis, diabetes mellitus, renal vascular disease and other kidney diseases. Anti-platelet drug use, vitamin K antagonist use, blood pressure and laboratory data were collected at 3 months after the start of dialysis, which was defined as baseline. Blood pressure was measured in the sitting position. Hypertension was defined as a systolic blood pressure !140 mmHg or use of anti-hypertensive agents. CHA 2 DS 2 -VASc scores were calculated (congestive heart failure ¼ 1 point, hypertension ¼ 1 point, age !75 years ¼ 2 points, age 65-74 years ¼ 1 point, diabetes mellitus ¼ 1 point, prior stroke ¼ 2 points, vascular disease including peripheral artery disease or myocardial infarction ¼ 1 point and female sex ¼ 1 point) [19, 20] , as were HAS-BLED scores (hypertension ¼ 1 point, kidney disease ¼ 1 point, liver cirrhosis ¼ 1 point, prior stroke ¼ 1 point, prior bleeding ¼ 1 point, age >65 years ¼ 1 point, predisposing medication use ¼ 1 point, drug or alcohol abuse history ¼ 1 point). The HAS-BLED score lacks one possible point for labile International Normalized Ratio (INR), since we had no data on INR. We had no data on the presence V i t a m i n K a n t a g o n i s t u s e i n d i a l y s i s p a t i e n t s
of atrial fibrillation. Serum haemoglobin, urea and creatinine were routinely measured in the dialysis centres at 3 months after start of dialysis. Residual glomerular filtration rate (GFR) was calculated as the mean of creatinine and urea clearance corrected for body surface area (mL/min/1.73 m 2 ).
Mortality
We classified causes of death according to the codes of the ERA-EDTA, which is a standardized classification of death causes in dialysis patients [18] . We grouped death causes into stroke, bleeding, cardiovascular and other. Stroke mortality was defined as death due to cerebrovascular accident (code 22). Bleeding mortality was defined as death due to haemorrhagic pericarditis ( 
Statistical analysis
Continuous variables are presented as median and interquartile range (IQR). Categorical variables are presented as percentages. Survival curves were determined with the KaplanMeier method and mortality rates/1000 person-years were calculated for vitamin K antagonist users and vitamin K antagonist non-users. We calculated crude and adjusted hazard ratios (HRs) with 95% CIs for all-cause and cause-specific (stroke, bleeding, cardiovascular and other) mortality within 5 years of follow-up using Cox proportional hazard regression analysis. In an additional analysis, we calculated HRs with 95% CIs for allcause and cause-specific mortality for dialysis patients with a CHA 2 DS 2 -VASc score 2, a CHA 2 DS 2 -VASc score 3 and a CHA 2 DS 2 -VASc score !4 as compared with a CHA 2 DS 2 -VASc score 1. Furthermore, we calculated crude and adjusted HRs with 95% CIs for all-cause mortality within 5 years of follow-up for vitamin K antagonist users as compared with vitamin K antagonist non-users within patients with a CHA 2 DS 2 -VASc score 1, a CHA 2 DS 2 -VASc score 2, a CHA 2 DS 2 -VASc score 3 and a CHA 2 DS 2 -VASc score !4. Finally, we calculated HRs with 95% CIs for all-cause mortality for vitamin K antagonist users as compared with vitamin K antagonist non-users for patients with a low CHA 2 DS 2 -VASc score (<2) and a low HAS-BLED score ( 3), a low CHA 2 DS 2 -VASc score and a high HAS-BLED score, a high CHA 2 DS 2 -VASc score and a low HAS-BLED score, and a high CHA 2 DS 2 -VASc score and a high HAS-BLED score. As a sensitivity analysis, we repeated the analyses for allcause mortality stratifying for dialysis modality. HRs were adjusted for age, sex, primary kidney disease, dialysis modality, hypertension, anti-platelet drug use, gastro-intestinal problems including bleeding, malignancy, cardiovascular disease (angina pectoris, myocardial infarction, heart failure, ischaemic stroke or claudication), GFR and haemoglobin levels. Propensity score matching was considered, but was not feasible due to a limited power. All analyses have been done in SPSS statistical software version 23.0 (IBM SPSS Statistics).
R E S U L T S
Baseline characteristics
Baseline characteristics are shown in Table 1 . Of the 1718 patients, 244 patients used vitamin K antagonists and 1474 patients did not use vitamin K antagonists. Vitamin K antagonist users were older, had more often haemodialysis as dialysis modality, had higher CHA 2 DS 2 -VASc scores, had more often cardiovascular diseases, used less often anti-platelet drugs and had lower haemoglobin levels than patients who did not use vitamin K antagonists.
Vitamin K antagonist use and mortality
During the 5 years of follow-up, 141 of the 244 vitamin K antagonist users and 540 of the 1476 vitamin K antagonist nonusers died, 66 vitamin K antagonist users and 700 vitamin K antagonist non-users were censored. Figure 1 shows the Kaplan-Meier survival curve with 5-year mortality as outcome. 
The Table 2) . Table 3 shows adjusted HRs for patients who used vitamin K antagonists as compared with patients who did not use vitamin K antagonists for stroke mortality (HR 1.5; 95% CI 0.6-4.0), bleeding mortality (HR 1.3; 95% CI 0.4-4.2), cardiovascular mortality (HR 1.2; 95% CI 0.9-1.8) and for other mortality (HR 1.2; 95% CI 0.8-1.6).
Vitamin K antagonist use and mortality in patients with low and high CHA 2 DS 2 -VASc scores
The risk of all-cause mortality, stroke mortality, bleeding mortality, cardiovascular mortality and other mortality increased with increasing CHA 2 DS 2 -VASc scores ( Table 4 ). The risk of allcause mortality increased with increasing CHA 2 DS 2 -VASc scores in both vitamin K antagonist users and non-users. Within patients with a low CHA 2 DS 2 -VASc score (score 1), vitamin K antagonist use was associated with a 2.8-fold (95% CI 1.1-7.9) increased mortality risk as compared with no vitamin K antagonist use after adjustment. There was no association between vitamin K antagonist use as compared with no vitamin K antagonist use within patients with a high CHA 2 DS 2 -VASc score (score !2). Within dialysis patients with a high CHA 2 DS 2 -VASc 
Years of follow-up
Survival (%) FIGURE 1: Kaplan-Meier curves for mortality of vitamin K antagonist (VKA) users and non-users.
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score, HRs were 0.9 (95% CI 0.5-1.6) for patients with a CHA 2 DS 2 -VASc score 2, 1.2 (95% CI 0.7-2.0) for patients with a CHA 2 DS 2 -VASc score 3 and 1.2 (95% CI 0.8-1.6) for patients with a CHA 2 DS 2 -VASc score !4 (Table 5 ). Due to a low number of events, it was not possible to investigate the association between vitamin K antagonists and cause-specific mortality for the different CHA 2 DS 2 -VASc scores. We calculated the all-cause mortality risks for vitamin K antagonist users as compared with vitamin K antagonist nonusers for low and high CHA 2 DS 2 -VASc and HAS-BLED scores. The adjusted HR for all-cause mortality in patients with a CHA 2 DS 2 -VASc score <2 and a HAS-BLED score 3 was 2.8 (95% CI 1.0-7.8), in patients with a CHA 2 DS 2 -VASc score !2 and a HAS-BLED score 3 this was 1.2 (95% CI 0.9-1.5) and in patients with a CHA 2 DS 2 -VASc score !2 and a HAS-BLED score >3 this was 1.0 (95% CI 0.3-2.9). There were no patients with a CHA 2 DS 2 -VASc score <2 and a HAS-BLED score >3.
Dialysis modality stratification
Stratifying for dialysis modality did not show any differences in the 5-year mortality risk between the two modalities for allcause mortality. In haemodialysis patients the adjusted HR was 1.2 (95% CI 0.9-1.5) and in peritoneal dialysis patients the adjusted HR was 1.4 (0.8-2.6). The risk of all-cause mortality increased in both dialysis modalities with increasing CHA 2 DS 2 -VASc scores (Table 6 ).
D I S C U S S I O N
In this prospective cohort study of 1718 incident dialysis patients with and without atrial fibrillation, we did not find a protective effect on mortality of vitamin K antagonists. Furthermore, we showed that the mortality risk increased with increasing CHA 2 DS 2 -VASc scores. In addition, it was shown that within patients with a CHA 2 DS 2 -VASc score 1, vitamin K antagonist use was associated with an increased mortality risk as compared with no vitamin K antagonist use, while vitamin K antagonist use within patients with a CHA 2 DS 2 -VASc score !2 was not associated with a protective effect on mortality.
Most of the previous studies that investigated the effect of vitamin K antagonists in dialysis patients with atrial fibrillation did not show a protective effect of vitamin K antagonists on stroke risk or survival [7] [8] [9] [10] [11] [12] [13] , while only two studies showed a decreased risk of stroke [5] or survival benefit [6] for vitamin K antagonist in dialysis patients with atrial fibrillation. The different conclusions in these two studies might be due to the lack of adjustment for confounding, and the inclusion of transplant patients in both studies. In our study, we found an increased allcause mortality risk.
As recommended by international guidelines, the CHA 2 DS 2 -VASc score is frequently used as risk stratification for stroke and to guide the decision to start oral anticoagulation therapy [1, 2] . These guidelines advise vitamin K antagonist use in patients with atrial fibrillation and a CHA 2 DS 2 -VASc score !2 [1, 2] . In our study, we found that stroke risks increased with increasing CHA 2 DS 2 -VASc scores, which is in line with previous studies in the general population [19, 20] . Since dialysis patients have an increased stroke risk, the same CHA 2 DS 2 -VASc scores probably reflects higher stroke risks in dialysis patients than subjects in the general population [21] [22] [23] . In our study, we found an increased mortality risk for vitamin K antagonist use in dialysis patients with a low CHA 2 DS 2 -VASc score. To our knowledge, we are the first to report an increased mortality risk for vitamin K antagonist use in dialysis patients with a CHA 2 DS 2 -VASc score 1. We did not find an association between vitamin K antagonist use and mortality in patients with a CHA 2 DS 2 -VASc score !2. Unfortunately, we had no data about the indication for vitamin K antagonist use to investigate whether differences were influenced by the indication for vitamin K antagonist use.
Stratification based on HAS-BLED scores did not show a change in mortality risk for the vitamin K antagonist users as Table 6 . CHA 2 DS 2 -VASc scores and all-cause mortality separated by dialysis modality compared with non-users. Vitamin K antagonist use versus non-use was not associated with a protective effect on mortality for patients with a low CHA 2 DS 2 -VASc score (<2) and a low HAS-BLED score 3, for patients with a high CHA 2 DS 2 -VASc score (!2) and a low HAS-BLED score 3, and for patients with a high CHA 2 DS 2 -VASc score (!2) and a high HAS-BLED score (>3). Since haemodialysis patients receive heparin during dialysis sessions, this might influence the mortality risk. However, we did not find different effects of vitamin K antagonist use in the different dialysis modalities on all-cause mortality.
There could be several pathophysiological explanations why vitamin K antagonist use in dialysis patients is not associated with a protective effect on mortality. This could be explained by an accelerated vascular calcification in dialysis patients due to the inhibition of matrix Gla protein induced by vitamin K antagonists [24] . Therefore, it could be that vitamin K antagonists are less effective in preventing stroke events in dialysis patients than in the general population [3] . Furthermore, pre-existing platelet dysfunction, altered clot properties resulting in denser clots with thinner fibrin fibres, routine heparin use during haemodialysis treatment and a suboptimal time in therapeutic range of vitamin K antagonists could lead to an increased bleeding risk in dialysis patients [16, 17, 25] .
Generally, the benefits of vitamin K antagonists for stroke prevention in atrial fibrillation need to be weighed against bleeding risks. Since there are no clinical trials that have investigated stroke and bleeding outcomes associated with vitamin K antagonist use in dialysis patients, guideline recommendations of vitamin K antagonist use in dialysis patients are based on observational studies. These guidelines have reported conflicting recommendations for vitamin K antagonist use in dialysis patients [1, 26, 27] . Current American College of Cardiology/American Heart Association atrial fibrillation guidelines report that in dialysis patients with a CHA 2 DS 2 -VASc score !2 it is reasonable to prescribe vitamin K antagonists. In contrast, the Canadian guidelines [26] and the Kidney Disease: Improving Global Outcomes guidelines [27] do not recommend routine anticoagulation treatment for dialysis patients with atrial fibrillation for the primary prevention of stroke events. Therefore, randomized controlled trials comparing vitamin K antagonists with placebo or direct oral anticoagulants are needed.
The general strength of this study was the large and welldefined Dutch cohort of incident dialysis patients with available data on many patient characteristics, laboratory measurements and death. However, our study has several potential limitations. The comparison between vitamin K antagonist use versus nonuse in an observational design makes confounding-byindication the most important limitation. In our analyses, we took this into account by correcting for several confounders, but this cannot exclude possible residual confounding. We considered using propensity score matching to adjust for the association between vitamin K antagonist use and mortality. Future studies should consider propensity score analyses in the association between vitamin K antagonist use and mortality. Furthermore, ERA-EDTA death codes make no distinction between death due to ischaemic or haemorrhagic stroke. Therefore, we could not investigate the association between vitamin K antagonist use and haemorrhagic or ischaemic stroke separately and we could not evaluate whether there was a shift from ischaemic stroke events towards haemorrhagic stroke events in patients with a CHA 2 DS 2 -VASc score !2. In addition, we had no information on the indication of vitamin K antagonist use in dialysis patients. Therefore, it could be that vitamin K antagonists were used for other indications than atrial fibrillation in dialysis patients with a low CHA 2 DS 2 -VASc score. However, based on the high risk of atrial fibrillation in dialysis patients, it is likely that an important proportion of these patients had atrial fibrillation [13] . In addition, it could be that at initiation of vitamin K antagonist use (before dialysis), the CHA 2 DS 2 -VASc score was higher than at baseline of start of dialysis. Furthermore, we had no information about the presence of atrial fibrillation in vitamin K antagonist non-users. However, more than one-third of dialysis patients without a diagnosis of atrial fibrillation suffer from paroxysmal atrial fibrillation [28] . These patients with undiagnosed atrial fibrillation who do not use vitamin K antagonists probably have an increased stroke risk, since other therapeutic options such as electric cardioversion or medication for rhythm control are not considered. Therefore, it could be that we overestimated the risk of stroke for vitamin K non-users. Another potential limitation is that we included dialysis patients who already used vitamin K antagonists, which could have led to an underestimation of the mortality risks associated with vitamin K antagonist use. Finally, we did not have enough power to investigate the association between vitamin K antagonists and cause-specific mortality for different CHA 2 DS 2 -VASc scores.
In conclusion, we showed that vitamin K antagonist use compared with no vitamin K antagonist use was associated with an increased all-cause mortality risk in dialysis patients. Furthermore, we showed that the mortality risk increased with increasing CHA 2 DS 2 -VASc scores. In addition, it was shown that within patients with a CHA 2 DS 2 -VASc score 1, vitamin K antagonist use was associated with an increased mortality risk as compared with no vitamin K antagonist use, while vitamin K antagonist use within patients with a CHA 2 DS 2 -VASc score !2 was not associated with an increased mortality risk. Randomized controlled trials comparing vitamin K antagonists with placebo or direct oral anticoagulants are needed to provide better insight into the adverse effects of vitamin K antagonists and to provide more personalized prescription of anticoagulant drugs in dialysis patients.
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